Strategic expansion Ionetix is actively expanding its radiopharmaceutical manufacturing footprint with a new facility expansion in Delta Township, adding a second cyclotron and an advanced isotope processing laboratory, which signals growing capacity and potential for increased regional sales of N-13 Ammonia and related radiopharmaceutical services.

Pay-by-dose model The company offers N-13 Ammonia through a pay-by-the-dose model with installation and ongoing operation costs covered by Ionetix, creating a compelling value proposition for providers seeking lower upfront capital and predictable dosing costs, a strong sales hook for hospital networks and PET programs.

Alpha therapy focus Ionetix is extending its radiopharmaceutical network to support development and commercialization of targeted alpha therapy, opening potential cross-sell opportunities to oncology programs and radiopharmacies seeking alpha-emitting tracers alongside diagnostics.

Investor and leadership signals Recent leadership appointment in investor relations and a private placement financing alongside strategic partnerships (e.g., Lilly investment) indicate strengthened financing, governance, and market credibility, which can accelerate enterprise sales conversations and multi-site deployments.

Integrated tech stack A technology-enabled operation leveraging advanced manufacturing and design tools (AutoCAD, SOLIDWORKS, WordPress, Zoho, HubSpot, DigitalOcean) supports scalable project delivery, customer relationship management, and online marketing efforts, enabling a structured sales process and faster onboarding of new PET programs.